Research at The Parkinson's Institute and Clinical Center found that intermittent nicotine treatment reduces medication-induced dyskinesias in Parkinson's disease models. This could lead to more effective and long-term treatment options for patients suffering from the condition.
The Parkinson's Institute has received a $1 million grant from the Valley Foundation to support its STOP PD program, which aims to identify compounds to halt Parkinson's disease progression. The new facility will enable expanded research and patient services, offering improved care for those diagnosed with Parkinson's.
Research highlights the role of pesticides, toxic agents, and inflammation in Parkinson's development, while also exploring potential neuroprotective agents like nicotine. The findings aim to better understand the disease process and develop preventive measures.
A five-year study by The Parkinson's Institute suggests that nicotine treatment can reduce dopamine cell damage in Parkinson's disease. This protective effect may explain the lower incidence of Parkinson's among smokers, and could potentially lead to new therapy options for early-stage patients.